Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Braftovi |
|---|---|
| Manufacturer | PIERRE FABRE MEDICAMENT |
| Prescription required | Yes |
Braftovi 75mg g lule,7plaquettes x 6(Encorafenib)
encorafenib
Description
Braftovi 75mg g lule,7plaquettes x 6(Encorafenib) is a medicine catalog record in the MediPriceHub database. Active ingredient: encorafenib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: PIERRE FABRE MEDICAMENT. Therapeutic category: Medicine Library > Oncology Medicines > Melanoma Medicines. Pack information: 75 7 x 6. Origin country or market: France. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
BRAFTOVI is a kinase inhibitor indicated: Melanoma Colorectal Cancer (CRC) Non-Small Cell Lung Cancer (NSCLC) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test. • in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑authorized test. • in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-authorized test, after prior therapy. • in combination with binimetinib, for the treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-authorized test.How to Use
Use encorafenib under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: encorafenib. Pack size: 75 7 x 6. Pack unit: box. Manufacturer: PIERRE FABRE MEDICAMENT. Origin country: France. Source category: Medicine Library > Oncology Medicines > Melanoma Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.